T 2000

Drug Profile

T 2000

Alternative Names: T-2000

Latest Information Update: 08 Jan 2014

Price : $50

At a glance

  • Originator Taro Pharmaceutical Industries
  • Class Antiepileptic drugs; Barbiturates; Neuroprotectants
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Epilepsy; Essential tremor; Myoclonus; Neurological disorders

Most Recent Events

  • 22 Sep 2010 Taro Pharmaceutical Industries has been acquired by Sun Pharmaceutical Industries
  • 10 Dec 2009 No development reported - Phase-I for Epilepsy in USA (PO)
  • 10 Dec 2009 No development reported - Preclinical for Neurological disorders in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top